6.7
Agonisti Adrenergici: Agenti a Doppia Azione
Gli agonisti adrenergici a doppia azione, come l'efedrina e la pseudoefedrina, agiscono direttamente e indirettamente sui recettori adrenergici. Quest…
Gli agonisti adrenergici ad azione mista agiscono direttamente stimolando gli adrenocettori e indirettamente rilasciando le catecolamine immagazzinate dalle terminazioni nervose.
A differenza delle catecolamine endogene, gli agonisti ad azione mista mancano di una porzione catecolare, il che li rende substrati poveri per metabolizzare gli enzimi, aumentando la loro durata d'azione.
Sia l'efedrina che la pseudoefedrina mostrano un'eccellente biodisponibilità orale e penetrazione nel SNC, ma sono meno potenti delle catecolamine.
L'efedrina, isolata dalla pianta di efedra, è stata utilizzata come simpaticomimetico attivo per via orale per il trattamento dell'asma.
Poiché l'efedrina provoca stimolazione cardiaca e vasocostrizione, viene utilizzata per il trattamento dell'ipotensione indotta dall'anestesia. Tuttavia, è un broncodilatatore meno potente dell'isoprenalina o dell'adrenalina.
Inoltre, i suoi effetti stimolatori centrali sono responsabili del suo abuso come potenziatore delle prestazioni.
La pseudoefedrina, un isomero dell'efedrina con un'azione più indiretta, è efficace per via orale e ha meno effetti sul SNC. Viene utilizzato principalmente come decongestionante.
Poiché è comunemente usato come precursore nella produzione illegale di metanfetamine, la sua vendita è strettamente regolamentata.
View the full transcript and gain access to JoVE Core videos
Q1: How do mixed-acting adrenergic agonists differ from direct-acting agents?
Mixed-acting adrenergic agonists both stimulate adrenoceptors directly and indirectly release stored catecholamines from nerve terminals, amplifying the adrenergic response. Direct-acting agents only bind to receptors. Mixed-acting agents like ephedrine and pseudoephedrine lack a catechol moiety, making them resistant to metabolic degradation and extending their duration of action compared to endogenous catecholamines.
Q2: Why do ephedrine and pseudoephedrine have better oral bioavailability than catecholamines?
Ephedrine and pseudoephedrine lack a catechol moiety, which makes them poor substrates for metabolizing enzymes. This structural difference prevents rapid degradation, increasing their oral bioavailability and allowing them to reach systemic circulation effectively. Their lipophilicity also enhances absorption and CNS penetration, though they remain less potent than endogenous catecholamines.
Q3: What are the main clinical uses of ephedrine?
Ephedrine is used orally as a sympathomimetic agent for treating asthma and managing anesthesia-induced hypotension due to its cardiac stimulation and vasoconstriction effects. However, it is a less potent bronchodilator than isoprenaline or adrenaline. Its central stimulatory effects have led to abuse as a performance enhancer, limiting its therapeutic application.
Q4: Why is pseudoephedrine primarily used as a decongestant rather than for asthma?
Pseudoephedrine, an ephedrine isomer with predominantly indirect action, is orally effective with fewer central nervous system effects than ephedrine. These reduced CNS effects make it suitable for nasal decongestant use without significant stimulatory side effects. Its indirect mechanism of action and safety profile favor its use for congestion relief over asthma treatment.
Q5: How does prior catecholamine depletion affect mixed-acting agonist response?
Mixed-acting adrenergic agonists depend on releasing stored neurotransmitters for their indirect effects. Prior treatment with catecholamine-depleting agents like guanethidine or reserpine significantly reduces the agonist response by eliminating available stored catecholamines. This demonstrates the importance of the indirect mechanism in mixed-acting agent efficacy.
Q6: Why is pseudoephedrine's sale strictly regulated?
Pseudoephedrine is commonly used as a precursor in illegal methamphetamine production. Due to this abuse potential, its sale is strictly regulated to prevent diversion for illicit drug synthesis. Despite its legitimate therapeutic use as a decongestant, regulatory restrictions limit its availability and distribution.
Q7: What structural feature allows mixed-acting agonists to resist enzymatic degradation?
Mixed-acting adrenergic agonists like ephedrine and pseudoephedrine lack a catechol moiety present in endogenous catecholamines. This absence makes them poor substrates for metabolizing enzymes, preventing rapid degradation and increasing their duration of action. This structural modification is key to their extended therapeutic effect compared to natural catecholamines.